New York-based Monteverde & Associates PC has opened formal investigations into the proposed mergers involving Non-Invasive Monitoring Systems, InMed Pharmaceuticals, Olin Corporation, and Huntsman Corporation. The firm, led by attorney Juan Monteverde, is scrutinizing these transactions to protect shareholder interests and ensure corporate compliance with securities regulations.
A clever solution to a common daily frustration has secured the top prize for Lily Napierkowski in the 2025 Mockett Design Competition. Her winning entry, "Hooke," reimagines the standard purse hook, blending minimalist aesthetics with the kind of practical utility that defines the company's long-standing design philosophy.
More than 950 delegates, including 24 ministers and multiple heads of state, gathered in Lomé, Togo, to finalize a roadmap for the Single African Air Transport Market. The five-day summit concluded with the adoption of the Lomé Declaration, a strategic mandate designed to lower costs and accelerate continental connectivity.
Investors who held shares of Graphic Packaging Holding Company between February 4, 2025, and February 2, 2026, are facing a July 6 deadline to join a class action lawsuit. The litigation alleges the company misled shareholders regarding its financial health, specifically masking struggles with inventory management, rising costs, and waning demand.
With $254 million in reported U.S. revenue for 2025, Sterling-based Cynet Group has secured the 106th position on Staffing Industry Analysts' annual list of the country’s top workforce providers. The firm’s growth is anchored primarily in the travel nursing and allied healthcare sectors, according to the latest industry data.
Investors who purchased Immutep Limited securities between March 24, 2025, and March 12, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is spearheading the litigation, alleging that the biotech company misled shareholders regarding the efficacy of its TACTI-004 clinical trial for eftilagimod alfa.
Shareholders of Immutep Limited are facing a July 6, 2026, deadline to join a class action lawsuit alleging the company misled the market regarding the efficacy of its TACTI-004 clinical trial. The litigation centers on claims that leadership concealed known failures while publicly touting the progress of its drug, eftilagimod alfa.
Before a single foundation is poured, the success of any land development project rests on a rigid sequence of technical assessments. Michael Cuppy, an engineering and surveying expert based in Pueblo, Colorado, outlines the critical pre-construction phases that define site viability and long-term project stability.
Investors who purchased Phreesia, Inc. stock between May 8, 2025, and March 30, 2026, face an approaching July 13 deadline to join a class action lawsuit. The litigation centers on claims that the healthcare technology firm misled shareholders regarding the stability of its revenue projections and pharmaceutical marketing growth.
A dramatic reversal in the corporate finance labor market has seen the 2026 Talent Shortage Index climb to 77%, a stark contrast to the 108% surplus recorded just one year prior. This shift marks the onset of a long-anticipated deficit among CPAs and accounting professionals across the United States.
Shareholders who bought Badger Meter stock between April 18, 2024, and April 16, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is seeking participants to allege that the company misled the market regarding its true financial health and revenue recognition practices.
A 23% plunge in ARS Pharmaceuticals stock followed the June 24, 2026, disclosure that the company’s drug, Neffy®, failed to secure any new commercial formulary additions during the July review cycle. The sharp market correction triggered a securities fraud investigation by law firm Levi & Korsinsky into the company’s prior commercial growth forecasts.
Shareholders of Badger Meter, Inc. are facing a potential recovery window following the filing of a class action lawsuit alleging the company misled the market. The litigation centers on claims that the firm misrepresented its financial health by pulling customer orders forward to bolster its public performance metrics.
A sharp 13–17% collapse in Hyliion Holdings' share price has triggered a formal investigation by the law firm Levi & Korsinsky. The slide followed a report from Pelican Way Research that questioned the legitimacy of a $133 million deal, which had previously served as a primary catalyst for the company's recent market rally.
Investors who purchased Embecta Corp. stock between November 25, 2025, and May 4, 2026, are being urged to join a class action lawsuit. The litigation claims the medical device company issued false fiscal projections while concealing significant operational hurdles within its core pen needle market.
As the USTR Section 301 investigation panel begins hearings on Brazil today, the advocacy group Consumer Action for a Strong Economy (CASE) is lobbying the Trump administration to reject proposed tariffs on lean beef imports, warning that such measures function as a direct tax on American household grocery bills.
Navigating the complexities of property protection requires more than just a standard policy. With Arizona-specific risks like monsoon winds and flash flooding, understanding the nuances of dwelling, liability, and personal property coverage is essential for homeowners looking to secure their financial stability against unexpected accidents and structural damage.
Investors who purchased Embecta Corp. securities between November 25, 2025, and May 4, 2026, face an August 17, 2026, deadline to join a class action lawsuit. The Schall Law Firm is spearheading the litigation, alleging that the company issued misleading fiscal guidance while concealing significant market headwinds.
The traditional "wait and see" approach to glaucoma and cataract care is fading in favor of proactive intervention. Dr. I. Paul Singh and Dr. R. Krishna Sanka of the Eye Centers of Racine and Kenosha argue that addressing ocular pressure and lens degradation early prevents permanent vision loss and enhances patient quality of life.
Investors who held Futu Holdings Limited stock between May 2023 and May 2026 are facing a potential recovery window following a class action lawsuit. The litigation targets the company for allegedly misleading shareholders regarding its compliance with Chinese regulatory licensing requirements.
Shareholders who purchased Futu Holdings Limited stock between May 24, 2023, and May 27, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is seeking investors who suffered financial losses due to the company’s alleged failure to maintain compliance with Chinese regulatory mandates.
Investors who purchased Peabody Energy Corporation securities between October 14, 2024, and May 4, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is seeking participants to allege that the coal producer misled the market regarding the operational viability of its Centurion mine.
Investors who purchased Peabody Energy stock between October 14, 2024, and May 4, 2026, are facing a legal deadline as a class action lawsuit accuses the company of misleading the market regarding production growth at its Centurion mine.
Investors who purchased ZoomInfo Technologies stock between November 3, 2025, and May 11, 2026, face a critical deadline as a class action lawsuit moves forward. The litigation centers on allegations that the company misled shareholders regarding the market demand for its AI-powered product suite.
The European Commission has authorized TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. This approval marks the first bispecific-based, chemotherapy-free treatment option in Europe for patients requiring second-line therapy, offering a new path to durable remission.
The European Commission has authorized the use of TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, marking the first time a chemotherapy-free, bispecific-based therapy has been approved for this condition in a second-line setting across Europe.
Hong Kong-based software developer iToolab has updated its WatsGo platform to allow users to restore WhatsApp data directly from iCloud without resetting their iPhones. The feature bypasses the standard requirement to uninstall and reinstall the application, streamlining the recovery of chats, photos, and videos for mobile users.
Investors who purchased Zoetis Inc. stock between January 14, 2025, and May 6, 2026, face a July 27 deadline to join a class action lawsuit. The litigation alleges that the company violated federal securities laws by issuing false statements regarding the performance of its core product lines, including Librela, Apoquel, and Cytopoint.
Investors who held Hub Group, Inc. stock between April 28, 2023, and May 11, 2026, are being urged to evaluate their legal options. The DJS Law Group has initiated a class action lawsuit against the transportation management company, alleging that inaccurate financial disclosures misled shareholders for over three years.
Investors who purchased Zoetis Inc. securities between January 14, 2025, and May 6, 2026, are being urged to join a class action lawsuit filed by The Schall Law Firm. The litigation centers on allegations that the pharmaceutical company provided false information regarding its veterinary medication performance.
